DLG4 and stroke disorder: An analogous peptide (Tat-GluN2B9c) targeting GluN2B-containing NMDARs interaction with PSD-95, which differs only by two amino acids with the TAT2A peptide used in our study, was recently tested in a phase 2 randomized double-blinded placebo-controlled clinical trial for stroke (Hill et al., 2012).